500129-84-0

Basic information

• Product Name: 1,6-Naphthyridine-7-carboxamide, 5-bromo-N-[(4-fluorophenyl)methyl]-8-[[(4-methylphenyl)sulfonyl]oxy]-
• CAS NO: 500129-84-0
• Molecular Formula: C23H17BrFN3O4S
• Molecular Weight: 530.374
• Mol File: 500129-84-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,6-Naphthyridine-7-carboxamide, 5-bromo-N-[(4-fluorophenyl)methyl]-8-[[(4-methylphenyl)sulfonyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-Naphthyridine-7-carboxamide, 5-bromo-N-[(4-fluorophenyl)methyl]-8-[[(4-methylphenyl)sulfonyl]oxy]-(500129-84-0)
• EPA Substance Registry System: 1,6-Naphthyridine-7-carboxamide, 5-bromo-N-[(4-fluorophenyl)methyl]-8-[[(4-methylphenyl)sulfonyl]oxy]-(500129-84-0)

Safety Data

• Hazardous Substances Data: 500129-84-0(Hazardous Substances Data)

Upstream product

• 410544-37-5 5-bromo-8-hydroxy-[1,6]naphthyridine-7-carboxylic acid methyl ester 
• 412334-35-1 3-{[methoxycarbonylmethyl-(toluene-4-sulfonyl)-amino]-methyl}-pyridine-2-carboxylic acid isopropyl ester 
• 118892-74-3 3-hydroxymethyl-pyridine-2-carboxylic acid isopropyl ester 
• 142777-96-6 isopropyl 3-(chlorocarbonyl)pyridine-2-carboxylate 
• 118892-73-2 2,3-pyridinedicarboxylic acid 2-(isopropyl ester) 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 410544-56-8 N-(4-fluorobenzyl)-8-hydroxy-5-bromo-1,6-naphthyridine-7-carboxamide 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1407998-41-7 C₂₃H₁₇BrF₂N₄O 
• 1407998-37-1 C₁₈H₁₆BrFN₄O₂ 
• 1407998-36-0 C₁₇H₁₄BrFN₄O 
• 1407998-38-2 C₂₃H₁₈BrFN₄O 
• 1407998-39-3 C₂₄H₂₀BrFN₄O 
• 1407998-40-6 C₂₄H₂₀BrFN₄O 
• 1223080-78-1 C₁₉H₁₉BrFN₅O 
• 1385841-22-4 C₃₅H₂₈Br₂F₂N₈O₂ 
• 1223080-80-5 C₁₈H₁₇BrFN₅O 
• 1223080-84-9 C₁₉H₁₆BrFN₄O₃ 
• 1223080-86-1 C₂₆H₂₃BrFN₅O₂ 
• 1223080-88-3 C₂₂H₂₅BrFN₅O 
• 1223080-89-4 C₂₂H₁₇BrFN₅O 
• 1223080-90-7 C₂₂H₁₇BrFN₅O 

Relevant articles and documents

Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties

Among a large number of HIV-1 integrase (IN) inhibitors, the 8-hydroxy-[1,6]naphthyridines (i.e., L-870,810) were one of the promising class of antiretroviral drugs developed by Merck Laboratories. In spite of its remarkable potency and efficacy, unfortun